Microbot Medical Inc. with ticker code (MBOT) have now 1 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 20 and 20 calculating the average target price we see 20. With the stocks previous close at 7.44 this now indicates there is a potential upside of 168.8%. There is a 50 day moving average of 7.61 and the 200 day moving average is 7.21. The company has a market capitalisation of $53m. Visit the company website at: http://www.microbotmedical.com
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body’s vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.